Open AccessBarriers to Single-Dose Intravesical Chemotherapy in Nonmuscle Invasive Bladder Cancer—What's the Problem?
Author(s) -
Clint Cary,
Laura G. Militello,
Paige DeChant,
Richard M. Frankel,
Michaël Koch,
Michael Weiner
Publication year - 2021
Publication title -
urology practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.396
H-Index - 11
eISSN - 2352-0787
pISSN - 2352-0779
DOI - 10.1097/upj.0000000000000174
Subject(s) - medicine , bladder cancer , mitomycin c , gemcitabine , urology , chemotherapy , cystectomy , oncology , cancer , surgery
The intravesical instillation of mitomycin C immediately following surgery for non-muscle invasive bladder cancer has been shown to be efficacious in reducing cancer recurrence. As a result, the American Urological Association adopted guidelines for non-muscle invasive bladder cancer care to support its use in low to intermediate risk patients. Despite this, urologists' use of this drug following transurethral resection of a bladder tumor (TURBT) has been reported as low as 5% or less. Our study objective was to better understand the barriers urologists experience in using mitomycin C.